Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes

Proceedings of the National Academy of Sciences, Volume 122, Issue 4, January 2025.
SignificanceDuring the recent COVID-19 pandemic, the pathogen SARS-CoV-2 continuously mutated to produce new strains, challenging the development of therapeutics. To develop a mutation-tolerant anti-infective drug, we focused on the fact that while …
Source : National Academy of Sciences